Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post‐Hoc Analysis of the GISSI‐HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure) Trial
Marco Dauriz(Ospedale di Bolzano), Gabriele Cenni(Mario Negri Institute for Pharmacological Research), Antonio Atzori(Mario Negri Institute for Pharmacological Research), Giacomo Levantesi(Mario Negri Institute for Pharmacological Research), F Rusconi, Salim Yusuf(Population Health Research Institute), Jay N. Cohn(University of Minnesota), Gian Luigi Nicolosi(Policlinico Universitario di Catania), Filippo Bambi(Mario Negri Institute for Pharmacological Research), Gianfranco Sinagra(Società Italiana di Cardiologia), Antonietta Ledda(Mario Negri Institute for Pharmacological Research), Roberto Latini(Mario Negri Institute for Pharmacological Research), Luigi Tavazzi(Maria Cecilia Hospital), Francesca Bianchini(University of Florence), Marino Scherillo(Ospedale Monaldi), Bertram Pitt(Bayer (Germany)), Alberto Volpi(Mario Negri Institute for Pharmacological Research), Daniele Bertoli(Ospedale San Paolo), Vittoriana Canu(Mario Negri Institute for Pharmacological Research), Barbara Bartolomei(Mario Negri Institute for Pharmacological Research), Simona Barlera(Mario Negri Institute for Pharmacological Research), Adriano Decarli(Mario Negri Institute for Pharmacological Research), Franco Cobelli, Giovanni Targher(Ospedale Sacro Cuore Don Calabria), Pier Luigi Temporelli(Fondazione Salvatore Maugeri), Martina Ceseri, G. Alongi(Mario Negri Institute for Pharmacological Research), Concetta Caporusso(Mario Negri Institute for Pharmacological Research), Desirée Bastarolo(Mario Negri Institute for Pharmacological Research), Fabio Maria Turazza, Cristina Opasich(Mario Negri Institute for Pharmacological Research), Maurizio Porcu(Azienda Ospedaliera G. Brotzu), Aldo P. Maggioni(Health Care Foundation), Roberto Marchioli(IQVIA (United Kingdom)), Donata Lucci, Enrico Geraci(Mario Negri Institute for Pharmacological Research), Maria Grazia Franzosi(Goethe University Frankfurt), Gianna Fabbri(Mario Negri Institute for Pharmacological Research), Claudio Fresco(Mario Negri Institute for Pharmacological Research), Philip A. Poole‐Wilson(Mario Negri Institute for Pharmacological Research), Fulvio Camerini(University of Trieste), Peter Sleight(Hamilton General Hospital), Gianni Tognoni(Mario Negri Sud Foundation), Lucio Gonzini, Franco Cosmi(Inserm), Iacopo Cangioli(Mario Negri Institute for Pharmacological Research)
Cited by 71
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k